Please assess the completion status of the following clinical trial:

Trial Title: A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Clinical diagnosis of CDAD plus laboratory diagnostic test~* No more than 24 hrs antimicrobial treatment for current CDAD episode~* No more than 3 episodes of CDAD in prior 12 months~* No previous episode of CDAD within 30 days of study enrollment~* Female subjects of childbearing potential must use adequate contraception~Exclusion Criteria:~* Life-threatening or fulminant colitis~* Concurrent use of antibiotics or any other treatments for CDAD~* History of inflammatory bowel disease (ulcerative colitis, Crohn's disease)~* Participation in other Clinical research studies within one month of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SMT19969 (Type: EXPERIMENTAL): 200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
- Vancomycin (Type: ACTIVE_COMPARATOR): 125 mg capsule four times a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).